

R&D Solutions

Leverage Pharmacokinetic data in PharmaPendium to inform drug development strategies



Sherry Winter, PhD
Sr. Solution Marketing Manager
s.winter.1@Elsevier.com



We suggest viewing the presentation in full screen



Questions?

- You are welcome to submit questions by using the “Ask a Question” feature on your screen.
- As many questions as possible will be answered after the webinar.
- Slides and the recording will be sent to you following the webinar and are also available in the PharmaPendium Help section

LIVE

ASK A QUESTION RATE THIS

ASK A QUESTION CLOSE X

Enter your question for the presenter

Not hearing audio? [Click here for help](#)

Type your question here...

SEND QUESTION

Agenda

- Brief PharmaPendium overview
- Focus on Pharmacokinetic data in PharmaPendium
- Examples:
 - Finding PK data for similar drugs
 - Finding information on the best preclinical model to use
 - Identifying if different patient populations impact PK data
 - Correlating observed DDI affects with PK data

Critical decision-support



- ✓ Leverage past drug approvals to inform bottleneck issues
- ✓ Design studies that provide the most meaningful data
- ✓ Reduce unnecessary preclinical and clinical costs by comparing your drug to successful ones
- ✓ Rapidly evaluate potential DDI risks


PharmaPendium

PharmaPendium supports decision-making throughout Drug Development



R&D Phase	Information in PharmaPendium helps you to:
Preclinical	<ul style="list-style-type: none">• Determine Drug Safety assessments on lead candidates• Anticipate drug-drug interactions and other adverse events• Optimize <i>in vivo</i> / <i>in vitro</i> study designs, select and prioritize leads• Increase chances of successful submissions to regulatory authorities based on past precedents• Leverage drug precedents to help translate preclinical data into human effects / outcomes
Clinical	<ul style="list-style-type: none">• Examine drug approval packages to inform clinical study designs (population, indications, endpoints, etc)
Post-launch	<ul style="list-style-type: none">• Leverage lessons learned to:<ul style="list-style-type: none">• Develop risk management and strategic programs,• Improve clinical trial design• Monitor AERS reports for to identify post marketing safety concerns

Integrated FDA/EMA Drug Approval Docs & extracted data



Content and value is continually growing

Source Documents

2.3M+

pages of FDA
approval
documents

215K+

pages of EMA
approval
documents

10.4M+

FDA AERS
reports

690K+

Pages from FDA
Advisory
Committee
Meetings

Extracted Data

4485

Drugs indexed
& fully
searchable

1.64M+

PK data lines

315K+

Metabolizing
enzyme and
transporter data
lines

1.71M+

safety data lines

2.71M+

efficacy data
lines

115K

activity data lines

Role	R&D Phase	Challenges
Pharmacokinetic Scientist	Preclinical	<ul style="list-style-type: none">• Effectively assessing and prioritizing lead candidates• Determining the best study designs• Interpreting Absorption, Distribution, Metabolism, Excretion (ADME) data on drug candidates and prioritizing candidates on deliverability• Helping to translate animal dosing and safety data to humans

How does PharmaPendium support Pharmacokinetic Scientists?

- Access safety, efficacy, PK and Metabolizing Enzymes and Transporter data to help inform drug development strategies.
 - Inform PK study design by looking at in vivo and in vitro models used to support preclinical and clinical research of similar drugs, drug classes.
 - Leverage lessons learned from precedents found in regulatory documents and extracted preclinical and clinical data from drug approvals.
 - Gain insights from comparative data on the translatability of preclinical experimental data.
 - Build models to compute potential PK properties for their drug candidates

Answer critical drug development questions, including:

- ✓ Is the drug safe and effective within the therapeutic window?
- ✓ How much drug gets to where it needs to go?
- ✓ What is the bioavailability of the drug?
- ✓ Which animal model translated the best to humans in drugs similar to the one in development?
- ✓ What is the maximum tolerated dose for drugs similar to the one under development?
- ✓ What new secondary experiments need to be run prior to submission, if any? How were these experiments designed?
- ✓ Can I cite a previously-run experiment from a similar drug?

Pharmacokinetic module

Absorption

Includes:


- % Absorbed
- Bioavailability
- Concentrations
- Fraction absorbed
- Time values



Binding

Includes:


- Cell binding
- Protein binding



Biotransformation

Includes:


- Enantiomeric ratio
- Metabolic ratio
- Metabolic stability
- Metabolic transformation



Distribution

Includes:


- Accumulation
- AUC
- Permeation
- Steady state
- Time value
- Tissue distribution
- Volume of distribution



Elimination

Includes:

- Clearance
- Excretion values
- Half life
- Rate constants
- Time



Species

Includes:

- Human (including subpopulation)
- Vertebrates
 - Birds
 - Fish
 - Mammals



$$\frac{-B \pm \sqrt{B^2 - 4ac}}{2a} = \frac{-(b/3a) \pm \sqrt{(b/3a)^2 - 4ac}}{2}$$

Demo

R&D Solutions

Thank You!
Any Questions?

For more information:

s.winter.1@elsevier.com

[Contact sales](#)

www.elsevier.com/rd-solutions

